N Engl J Med 383:14251435 McMurray JJV, Solomon SD, Inzucchi SE, Kber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Blohlvek J, Bhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukt A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, OMeara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjstrand M, Langkilde AM (2019) DAPA-HF Trial Committees and Investigators
The body is simply recalibrating to a new metabolic baseline
Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa
Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus, administered as a once-weekly subcutaneous injection
Im watching for improvements in CRP and other inflammatory indicators because those improvements predict mood benefits